Guide to Mod GRF 1-29 & GHRP-6 Peptide Blend
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic peptide developed to stimulate the release of growth hormone from the pituitary gland by mimicking the effects of ghrelin. It is classified as ghrelin mimetic or GHS. It is composed of six amino acids and is classified as a hexapeptide. GHRP-6 has been studied for its potential, including in the mitigation of growth hormone deficiency and cachexia (muscle wasting). (1)
Modified (Mod) GRF 1-29, also known as CJC-1295 without DAC, is a synthetic peptide developed to act as a growth hormone-releasing hormone (GHRH) analog. It comprises 29 amino acids and is a tetrasubstituted version of the GRF 1-29 (also known as Sermorelin). GRF 1-29 is the smallest fragment of the GHRH peptide sequence, which may have the same potential for stimulating growth hormone release.
As summarized below, researchers have studied the peptides independently and for different potential action. GHRP-6 is suggested to induce potential action in:
- possible increased appetite
- possible improved muscle growth
- possible weight gain
- possible enhancement of immune function and tissue repair
Mod GRF 1-29 has been primarily researched for its potential to stimulate the release of growth hormone from the pituitary gland, which can have a range of actions. These may include the following:
- possible increased muscle mass
- possible decreased body fat
- possible improved bone density
- possible increased energy levels
Research and Clinical Studies
Mod GRF 1-29 & GHRP-6 Peptide and Muscle Mass
GHRP-6 and Mod GRF 1-29 have been suggested by researchers to exert anabolic properties by increasing growth hormone levels. For example, clinical studies with GRF 1-29 suggest that it may increase nocturnal growth hormone levels, serum levels of IGF-I and IGFBP-3, and GHBP concentrations.(2) As a result, male test subjects who were presented the peptide for four months reportedly experienced a significant increase in lean body mass by 1.26 kg. Yet, the study suggests that GHRH analog presentation may induce anabolic effects. The peptide also appeared to induce a possible increase in skin thickness in male subjects and possible improved insulin sensitivity.
Another trial supported the hypothesis that GRF (1-29) might increase GH and IGF-I levels and improve skeletal muscle function and metabolism in ambulatory, non-obese subjects aged 64 to 76 years with low baseline IGF-I.(3) More specifically, GRF (1-29) appeared to increase mean nocturnal GH release, GH peak amplitude, and two measures of muscle strength and a muscle endurance test.
GHRP-6 also may have anabolic potential, according to studies which are likely mediated via its growth hormone and IGF-1 stimulating action. One experiment with cultured myoblast cells reported that the peptide appeared to increase the expression of myogenic marker proteins, insulin-like growth factor-1, collagen type I, and metabolic activity in the myoblasts.(4) Thus, the scientists concluded that the peptide GHRP-6 might improve muscle condition by stimulating collagen type I synthesis and key proteins.
Mod GRF 1-29 & GHRP-6 Peptide and Growth Hormone Deficiency
GRF 1-29 and GHRP-6 have been investigated for their potential to stimulate growth in GH deficient subjects, and clinical trials suggest potential. One clinical study investigated the potential of GRF 1-29 for subjects with growth hormone deficiency.(5) In total, 110 subjects were given the peptide once daily for up to 1 year, and the main outcomes measured were linear growth enhancement and bone age progression. The peptide appeared to exhibit a significant increase in height velocity, with 74% of the subjects having a reportedly enhanced response after six months. The bone age to height age ratio was reported to remain stable. The researchers concluded, “No change in fasting glucose concentration or excessive generation of insulin-like growth factor I occurred, and overall GHRH was well tolerated.”
Another clinical trial aimed to investigate the potential of GHRP-6 in stimulating growth hormone (GH) secretion in subjects with normal height.(6) The study included 13 subjects, and the results suggested that the GH response to GHRP-6 was reportedly significant and comparable to that of other GHSs.
Mod GRF 1-29 & GHRP-6 Peptide and Wasting, Cachexia
Mod GRF 1-29 and GHRP-6 may have the potential to increase growth hormone and IGF-1 levels, which may have anti-catabolic actions on muscle tissue. For example, GRF 1-29 was suggested to significantly increase growth hormone peak levels in subjects, even though the potential was slightly attenuated in those with growth hormone deficiency.(7) Despite no direct research on Mod GRF 1-29 (without DAC), studies on Mod GRF 1-29 with DAC report apparently increased HGH and IGF-1 levels in the test subjects.(8)
GHRP-6 may also cause a dramatic increase in growth hormone levels in subjects, according to researchers in clinical trials. For example, Cordido et al. suggested that GHRP-6 might increase GH secretion in 19 obese subjects.(9) The scientists noted that GHRP-6 appeared more impactful than GHRH alone, stating, “GH responses to GHRP-6 were almost twice those to GHRH in obese patients.” GHRP-6 was developed with the intention of having potential as a ghrelin mimetic. Studies suggest that mimetics have shown promise in reversing protein breakdown and weight loss in catabolic states.(10) Ghrelin has various potential actions on regulating appetite, body composition, growth hormone secretion, and energy expenditure. It may also have anti-inflammatory, anti-apoptotic, and anxiolytic potential as well.
Mod GRF 1-29 & GHRP-6 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
- Cabrales, A., Gil, J., Fernández, E., Valenzuela, C., Hernández, F., García, I., Hernández, A., Besada, V., Reyes, O., Padrón, G., Berlanga, J., Guillén, G., & González, L. J. (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine healthy male volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 48(1-2), 40–46. https://doi.org/10.1016/j.ejps.2012.10.006
- Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
- Vittone, J., Blackman, M. R., Busby-Whitehead, J., Tsiao, C., Stewart, K. J., Tobin, J., Stevens, T., Bellantoni, M. F., Rogers, M. A., Baumann, G., Roth, J., Harman, S. M., & Spencer, R. G. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: clinical and experimental, 46(1), 89–96. https://doi.org/10.1016/s0026-0495(97)90174-8
- Lim, C. J., Jeon, J. E., Jeong, S. K., Yoon, S. J., Kwon, S. D., Lim, J., Park, K., Kim, D. Y., Ahn, J. K., & Kim, B. W. (2015). Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I. BMB reports, 48(9), 501–506. https://doi.org/10.5483/bmbrep.2015.48.9.258
- Thorner, M., Rochiccioli, P., Colle, M., Lanes, R., Grunt, J., Galazka, A., Landy, H., Eengrand, P., & Shah, S. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. The Journal of clinical endocrinology and metabolism, 81(3), 1189–1196. https://doi.org/10.1210/jcem.81.3.8772599
- Bellone, J., Ghizzoni, L., Aimaretti, G., Volta, C., Boghen, M. F., Bernasconi, S., & Ghigo, E. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. European journal of endocrinology, 133(4), 425–429. https://doi.org/10.1530/eje.0.1330425
- Achermann, J. C., Hindmarsh, P. C., Robinson, I. C., Matthews, D. R., & Brook, C. G. (1999). The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals. Clinical endocrinology, 51(5), 575–585. https://doi.org/10.1046/j.1365-2265.1999.00839.x
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004
- Khatib, M. N., Gaidhane, A., Gaidhane, S., & Quazi, Z. S. (2018). Ghrelin as a Promising Therapeutic Option for Cancer Cachexia. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 48(5), 2172–2188. https://doi.org/10.1159/000492559
NOTE: These products are intended for laboratory research use only. Mod GRF 1-29 & GHRP-6 peptide blend for sale (10mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.